SDC Table 1. Clinical characteristics of patients with biopsies containing ≥15 eosinophils/hpf after second review but not pathology report

Patient #1 / Pathology
report
count
(eosinophils/
hpf) / Second
review
count
(eosinophils/
hpf) / Initial or follow-up endoscopy / EoEdiagnosis / PPIconfirmation at diagnosis, dose / Treatment at time of listed endoscopy / Treatment change after listed endoscopy
1 / 0 / 17 / Follow-up / Yes / Yes, lansoprazole 15 mg/day / Elimination diet, food trialing / Endoscopy considered normal, continued to reintroduce foods
2 / 2 / 16 / Follow-up / Yes / Yes, lansoprazole 15 mg/day / Elemental diet, food trialing / Endoscopy considered normal, continued to reintroduce foods
3 / 3 / 26 / Follow-up / Yes / No, on ranitidine at time of initial diagnostic endoscopy / Elimination diet, budesonide / Discontinued budesonide but had active EoE in subsequent endoscopies and resumed budesonide treatment
4 / 3 / 22 / Follow-up / Yes / Yes, unable to determine dose / Elimination diet, food trialing / Continued to reintroduce foods
5 / 4 / 32 / Follow-up / No / No PPI at time of diagnosis but on PPI at time of listed endoscopy (lansoprazole 15 mg 2X/day) / Elimination diet / No changes to treatment
6 / 4 / 41 / Follow-up / Yes / Yes, lansoprazole 30 mg/day / Fluticasone propionate / Weaned lansoprazole, decreased fluticasone propionate dose
7 / 5 / 15 / Follow-up / Yes / Yes, lansoprazole 15 mg/day / Elemental diet, food trialing / Continued to reintroduce foods
8 / 7 / 20 / Follow-up / Yes / Yes, lansoprazole 15 mg/day / Elimination diet, food trialing / No changes to treatment, planning to reintroduce food
9 / 7 / 20 / Follow-up / Yes / Yes, lansoprazole 15 mg 2X/day / Elimination diet / No changes to treatment, considering tapering lansoprazole
10 / 7 / 15 / Follow-up / Yes / Yes, lansoprazole 15 mg/day / Elemental diet / No changes to treatment, considering reintroducing foods
11 / 8 / 16 / Follow-up / Yes / No / Self-directed avoidance of foods2, oral prednisone / Discontinued prednisone
12 / 8 / 18 / Follow-up / Yes / Yes, unable to determine dose3 / Elemental diet, food trialing / Current diet maintained
13 / 9 / 16 / Follow-up / Yes / No PPI at time of diagnosis but on PPI at time of listed endoscopy (omeprazole 20 mg/day) / Elimination diet / Continued to eliminate foods
14 / 9 / 21 / Follow-up / Yes / Yes, lansoprazole 30 mg 2X/day / Elimination diet, fluticasone propionate / Increased fluticasone propionate dose
15 / 9 / 16 / Follow-up / Yes / Yes, lansoprazole 15 mg/day / Elemental diet / Continued with elemental diet, considering reintroducing foods
16 / 10 / 27 / Follow-up / Yes / Yes, lansoprazole 15 mg 2X/day / Elimination diet, budesonide / No changes to current treatment for reflux and EoE
17 / 10 / 35 / Follow-up / Yes / Yes, omeprazole 20 mg/day / Elimination diet, fluticasone propionate / Discontinued fluticasone propionate and began elemental diet
18 / 10 / 38 / Follow-up / Yes / Yes, lansoprazole 30 mg/day / Elimination diet, fluticasone propionate / No changes to treatment
19 / 10 / 16 / Follow-up / Yes / Yes, lansoprazole 15 mg/day / Elimination diet, food trialing / Endoscopy considered normal, continued to reintroduce foods
20 / 10 / 24 / Follow-up / Yes / Yes, unable to determine dose3 / Elimination diet, food trialing / Continued to reintroduce foods
21 / 12 / 42 / Follow-up / Yes / Yes, lansoprazole 15 mg 2X/day / Elimination diet / No changes to treatment
22 / 14 / 25 / Initial / No / No / None / Began lansoprazole but had no subsequent endoscopy at CCHMC
23 / 14 / 55 / Follow-up / Yes / Yes, omeprazole 10 mg/day / Fluticasone propionate / No changes to treatment
24 / 14 / 58 / Follow-up / Yes / Yes, omeprazole 20 mg/day / Elimination diet, food trialing / Discontinued current food trial

1De-identified number assigned to patient on the basis of increasing eosinophil count in pathology report

2Avoidance of foods based on patient preference, not physician- or skinprick test–directed

3Dose not listed in electronic medical documents

CCHMC, Cincinnati Children’s Hospital Medical Center; EoE, eosinophilic esophagitis; hpf, high-power field; PPI, proton pump inhibitor; 2X, twice